form10q_063010.htm

10-Q 1 form10q_063010.htm FORM 10Q 6-30-10 form10q_063010.htm

United States

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2010

Commission File Number 0-20791

AMARILLO BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

TEXAS		75-1974352
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)


4134 Business Park Drive, Amarillo, Texas 79110
(Address of principal executive offices) (Zip Code)


(806) 376-1741
(Issuer’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [√ ] Yes [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]		Accelerated filer [ ]
Non-accelerated filer [ ] (do not check if smaller reporting company)		Smaller reporting company [√]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)[ ] Yes [√] No

As of August 17, 2010 there were 54,591,247 shares of the issuer's common stock and 650 shares of the issuer’s preferred stock outstanding.

AMARILLO BIOSCIENCES, INC.

INDEX

		PAGE NO.
PART I:	FINANCIAL INFORMATION
ITEM 1.	Financial Statements
	Balance Sheets– June 30, 2010 (unaudited) and December 31, 2009	3
	Statements of Operations – Three and Six Months Ended June 30, 2010 and 2009 (unaudited)	4
	Condensed Statements of Cash Flows – Six Months Ended June 30, 2010 and 2009 (unaudited)	5
	Notes to Financial Statements (unaudited)	6
ITEM 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	9
ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk.	16
ITEM 4.	Controls and Procedures	19

PART II:	OTHER INFORMATION
ITEM 1.	Legal Proceedings	20
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20
ITEM 3.	Defaults Upon Senior Securities	22
ITEM 4.	Submission of Matters to a Vote of Security Holders	22
ITEM 5.	Other Information	22
ITEM 6.	Exhibits……………………………………………………………	22
Signatures		23

PART I - FINANCIAL INFORMATION

ITEM 1.

Financial Statements

Amarillo Biosciences, Inc.

Balance Sheets

	June 30, 2010			December 31, 2009
Assets	(unaudited)
Current assets:
Cash and cash equivalents	$	21,300			$	24,216
Other current assets		81,786				87,208
Total current assets		103,086				111,424
Property, equipment, and software, net		2,816				4,321
Patents, net		120,023				123,184
Total assets	$	225,925			$	238,929

Liabilities and Stockholders' Deficit
Current liabilities:
Accounts payable and accrued expenses	$	492,187			$	318,550
Accrued interest - related party		705,924				661,294
Accrued expenses – related party		78,360				78,360
Derivative liabilities		1,080,330				1,928,120
Notes payable - related party		2,000,000				2,000,000
Total current liabilities		4,356,801				4,986,324
Total liabilities		4,356,801				4,986,324

Commitments and contingencies

Stockholders' deficit
Preferred stock, $0.01 par value:
Authorized shares - 10,000,000
Issued and outstanding shares – 0 at June 30, 2010 and December 31, 2009		-				-
Common stock, $0.01par value:
Authorized shares - 100,000,000
Issued and outstanding shares – 54,564,416 at June 30, 2010 and 52,041,001 at December 31, 2009		545,644				520,410
Additional paid-in capital		30,351,493				30,051,134
Accumulated deficit		( 35,028,013	)			( 35,318,939	)
Total stockholders' deficit		(4,130,876	)			( 4,747,395	)
Total liabilities and stockholders’ deficit	$	225,925			$	238,929

See accompanying notes to financial statements.

Amarillo Biosciences, Inc.

Statements of Operations

(Unaudited)

	Three months ended June 30,						Six months ended June 30,
	2010			2009			2010			2009

Revenues:
Dietary supplement sales	$	3,024		$	96		$	3,120		$	228
Sublicense fee revenue		-			13			-			795
Total revenues		3,024			109			3,120			1,023
Cost of revenues:
Product sales		2,038			28			2,095			54
Sublicense fee revenues		-			7			-			397
Total cost of revenue		2,038			35			2,095			451
Gross Margin		986			74			1,025			572

Operating expenses:
Research and development expenses		97,831			108,986			199,119			279,937
Selling, general and administrative expenses		137,403			434,564			312,567			682,088
Total operating expenses		235,234			543,550			511,686			962,025

Operating loss		(234,248	)		(543,476	)		(510,661	)		( 961,453	)

Other income (expense)
Change in fair value of derivatives		784,056			(1,867,012	)		847,790			(1,991,736	)
Interest expense		(23,575	)		(22,855	)		(46,343	)		(45,710	)
Interest and other income		140			1,431			140			3,391
Net income (loss)	$	526,373		$	(2,431,912	)	$	290,926		$	(2,995,508	)

Basic net income ( loss) per share	$	0.01		$	(0.06	)	$	0.01		$	(0.07	)
Diluted net income ( loss) per share	$	0.01		$	(0.06	)	$	0.01		$	(0.07	)

Basic weighted average shares outstanding		53,911,830			43,411,139			53,356,757			40,891,257
Diluted weighted average shares outstanding		53,911,830			43,411,139			56,410,440			40,891,257

See accompanying notes to financial statements.

Amarillo Biosciences, Inc.

Condensed Statements of Cash Flows

(Unaudited)

	Six months ended June 30,
	2010			2009

Net cash used in operating activities	$	( 206,033	)	$	( 558,180	)

Cash from investing activities:
Patent expenditures		( 5,083	)		( 858	)
Net cash used in investing activities		( 5,083	)		( 858	)

Cash from financing activities:
Proceeds from exercise of options		8,200			-
Proceeds from sale of common stock		200,000			552,029
Net cash provided by financing activities		208,200			552,029

Net increase (decrease) in cash		(2,916)			(7,009)
Cash and cash equivalents at beginning of period		24,216			10,853
Cash and cash equivalents at end of period	$	21,300		$	3,844
Supplemental disclosure of cash flow information
Cash paid for interest	$	1,713		$	1,201
Cash paid for income taxes		-			-

See accompanying notes to financial statements.

Amarillo Biosciences, Inc.

Notes to Financial Statements

(Unaudited)

Basis of presentation. The accompanying financial statements, which should be read in conjunction with the financial statements and footnotes included in the Company's Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission, are unaudited, but have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2010 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2010.

Financial Condition. Our viability as a company is dependent upon successful commercialization of products resulting from its research and product development activities. We plan on working with commercial development partners in the United States and in other parts of the world to provide the necessary sales, marketing and distribution infrastructure to successfully commercialize the interferon alpha product for both human and animal applications. Our products will require significant additional development, laboratory and clinical testing and investment prior to obtaining regulatory approval to commercially market our product(s). Accordingly, for at least the next few years, we will continue to incur research and development and general and administrative expenses and may not generate sufficient revenues from product sales or license fees to support its operations.

The Company continues to pursue a broad range of financing alternatives to improve its financial condition. These alternatives may include the sale or issuance of a substantial amount of common stock, common stock warrants or stock options. These financing alternatives could require an increase in the number of authorized shares of the Company’s common stock and result in significant dilution to existing shareholders and, possibly, a change of control of the Company.

Common Stock. The shareholders have authorized 100,000,000 shares of voting common shares for issuance. On June 30, 2010, a total of 81,276,512 shares of common stock were either outstanding (54,564,416) or reserved for issuance upon exercise of options and warrants (26,712,096). Common stock issuances in the first and second quarters of 2010 are as follows:

Common Stock Issued in Q1 2010	Shares	Issue Price	Net Price
Private placements – cash	1,060,000	$ 0.10	$ 103,000
Directors, officers, consultants plan – services	145,814	0.105-0.16	19,130
Options exercised – cash	82,000	0.10	8,200
Options exercised – cashless	70,258	0.10	-
Total Common Stock Issued in Q1 2010	1,358,072	$0.105-0.16	$130,330

Brokerage commissions totaled $3,000 during the first quarter of 2010. Net price above reflects net proceeds after commissions are deducted. Private placement stock issued during the first quarter of 2010 included 100% warrant coverage (1,060,000 warrants) with $0.10 exercise price and 3-year term.

Common Stock Issued in Q2 2010	Shares	Issue Price	Net Price
Private placements – cash	1,075,000	$ 0.10	$ 97,000
Directors, officers, consultants plan – services	90,343	0.08-0.105	8,630
Total Common Stock Issued in Q2 2010	1,165,343	$0.08-0.105	$ 105,630

Brokerage commissions totaled $10,500 during the second quarter of 2010. Net price above reflects net proceeds after commissions are deducted. Private placement stock issued during the second quarter of 2010 included 100% warrant coverage (1,075,000 warrants) with $0.10 exercise price and 3-year term.

The common stock issuances above do not trigger any reset provisions of previously issued securities. The issuances of common stock with prices below $0.10 per share that are issued to employees, directors or consultants pursuant to stock plans approved by a majority of the non-employee directors are exempt issuances.

Common Stock Options. We recognized $80,752 of employee options expense, related to previously issued options during the six months ended June 30, 2010. The remaining cost expected to be recognized if these options vest is $32,122. The Board granted 100,000 options with 2-year term and $0.11 exercise price to a consultant on March 8, 2010 with a fair value of $8,852. One quarter of the options (fair value $2,213) vest each quarter during 2010. An officer and a consultant exercised 245,000 options in 2010. See “6. Stock Option and Warrant Exercise Incentive” below for more details about 2010 stock option exercises. Options for the purchase of 201,667 shares expired during the period ending March 31, 2010. No options expired during the second quarter of 2010.

Common Stock Warrants. Private placement stock (1,060,000 shares) issued at $0.10 per share during the first quarter of 2010 included 1,060,000 warrants with $0.10 exercise price and 3-year term. We received $103,000 of net proceeds. Private placement stock (1,075,000 shares) issued at $0.10 per share during the second quarter of 2010 included 1,075,000 warrants with $0.10 exercise price and 3-year term. We received $97,000 of net proceeds.

Warrants issued in connection with a preferred stock financing in the first quarter of 2008 (“Firebird warrants”) have an embedded derivative feature (full-ratchet anti-dilution provision).We are at risk of triggering the warrant anti-dilution provisions of previously issued warrants if we sell stock below $0.10 per share to any non-exempt parties. Options and warrants issued prior to January 8, 2008 plus officers, directors and consultants under stock plans approved by outside board of director members are exempt from the anti-dilution provisions. In accordance with Financial Account Standards Board Accounting Standards Codification (“FASB ASC”) Topic 815, the Company reclassified the warrants to liabilities at fair value on January 1, 2009 and reported the change in fair value of the warrants at the end of each quarter to June 30, 2010.

The binomial Black-Scholes pricing model was used to calculate the fair value of the warrants with embedded features on June 30, 2010. The probability of not triggering the reset at $0.10 per share was estimated as 25% since the stock closing price was $0.07 on June 30, 2010. The probability of private placement issuances triggering a reset was estimated as 75%.

The Black-Scholes option-pricing model was utilized with the following assumptions: dividend yield 0.0%, expected volatility 168.2%, risks free interest rate 1.0%, and expected life of approximately 2.53 years. The valuation for the remaining 12,447,999 warrants outstanding was $1,080,330 on June 30, 2010. The derivative gain for the first six months of 2010 was $847,790.

6. Stock Option and Warrant Exercise Incentive

On November 9, 2009 the Board approved incentives to encourage option and warrant holders to exercise options and warrants. Option and Warrant holders exercised up to one third of the options or warrants they held, at a price of $0.10 per share cash to the Company, and for each option or warrant so exercised, two were converted to cashless options/warrants with an exercise price of $0.10 per share, and deemed exercised immediately, on a cashless basis. The Board extended the exercise incentive until January 22, 2010.

The Company determined that this was a modification of equity instruments, and accounted for the inducement under ASC Topic 718. For option and warrant holders who accepted the inducement and exercised their instruments under the terms noted above, an incremental fair value of the inducement was determined using the Black-Scholes option pricing model, with the following assumptions: dividend yield 0.0%, expected volatility of 149-193%, risk free interest rate 0.16 -2.37%, and expected life of 0.61-4.27 years. The Company recognized $4,456 of expense related to the inducement in the first quarter of 2010. See summary of the exercise incentive transactions below:

	Options/Warrants Exercised Q1 2010	Common Stock Issued	Release of Reserved into Available Shares	Net Cash to Company
Options	245,000	152,258	92,742	$ 8,200
Warrants	-	-	-	-
Total	245,000	152,258	92,742	$8,200

No options or warrants were exercised during the second quarter of 2010.

7.	Notes Payable – Related Party. Two $1,000,000 notes are payable under an unsecured loan agreement with Hayashibara Biochemical Laboratories, Inc. (“HBL”), a major stockholder, dated July 22, 1999. Although we are currently in repayment default on the notes, HBL has not demanded payment.

8.	Line of Credit. We have a line of credit with Wells Fargo for $20,000, with an interest rate of prime rate plus 6.75 percent. There was an outstanding balance on June 30, 2010 of $19,381 which is included in accounts payable.

9.	License and Sublicense Agreements. During the first six months of 2010 no license fees were received.

On January 7, 2010, we entered into a License and Supply agreement with Intas Pharmaceuticals Ltd., an India-based pharmaceutical company with three decades of experience in the healthcare industry and a global presence in 42 countries worldwide. Under the terms of the agreement, Intas will pay the Company a royalty on net sales in India and Nepal after marketing approval is obtained.

10.

Related Party Transactions. The Company engaged the law firm of Underwood, Wilson, Berry, Stein and Johnson P.C. of which Mr. Morris is a shareholder. Mr. Morris is also the Secretary of the Company. During the six months ended June 30, 2010 the Company incurred approximately $14,656 of legal fees from this law firm.

11.	Subsequent Events. Since June 30, 2010, the Company sold 2,000 unregistered shares of common stock for $0.10 per share together with 2,000 warrants with 3-year term and exercisable at $0.10 per share. Net proceeds totaled $200.

The Board of directors authorized the issuance of up to 10,000 shares of series 2010-A 10% Convertible Preferred Stock on July 29, 2010. Each preferred share is convertible into 1,000 common shares ($100 stated value per share divided by $0.10). Dividends are payable quarterly at 10% per annum in cash or stock at the option of the preferred stock Holder. Stock dividend payments are valued at the higher of $0.10 per share of common stock or the average of the two highest volume weighted average closing prices for the 5 consecutive trading days ending on the trading day that is immediately prior to the dividend payment date.

Since June 30, 2010, the Company sold 650 shares of Series 2010-A 10% Convertible Preferred Stock with $0.01 per share par value and $100 per share stated value. Net proceeds after $6,500 of brokerage commissions totaled $58,500.

On July 29, 2010, the Board of Directors authorized the issuance of 1,050,000 options with 5-year term and $0.065 strike price to employees and directors (fair value $67,739) under the 2009 A Officers, Directors, Employees, and Consultants Non-Qualified Stock Option Plan.

On July 31, 2010, the Company issued 24,831 shares of common stock to a consultant for services valued at $1,614.

The above preferred stock, common stock and stock option issuances do not trigger any reset provisions of previously issued securities. The issuances with common stock and option strike prices below $0.10 per share of common stock that are issued to employees, directors or consultants pursuant to stock or option plans approved by a majority of the non-employee directors are exempt issuances.

ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our financial statements and the notes thereto which appear elsewhere in this report. The results shown herein are not necessarily indicative of the results to be expected in any future periods. This discussion contains forward-looking statements based on current expectations, which involve uncertainties. Actual results and the timing of events could differ materially from the forward-looking statements as a result of a number of factors. Readers should also carefully review factors set forth in other reports or documents that we file from time to time with the Securities and Exchange Commission.

Company Goal – FDA Approval and Commercialization of Oral Interferon.

Amarillo Biosciences, Inc. (OTCBB: AMAR), is the world leader in the development of low-dose interferon for oral delivery and is conducting Phase 2 clinical studies testing oral interferon in animal and human diseases. We have changed our focus from Orphan Diseases (small markets) to treatment of diseases with large markets to attract large pharma partners. Our funding strategy is to seek private placement and partner funding to complete Phase 2 clinical studies for influenza, chronic cough in COPD patients, and hepatitis C; then seek large pharma partners to fund and help with the regulatory approval process in the US and Europe. We believe that our technology and the large, billion-dollar markets for these disease indications will attract global pharma partners sometime later this year or early next year.

Intellectual Property

Our portfolio consists of patents with claims that encompass method of use or treatment with interferon and composition of matter and manufacturing. We currently own or license six patents and two pending patents related to low-dose orally delivered interferon, and one issued patent on our dietary supplement. We have completed more than 100 pre-clinical (animal) and human studies of the safety and efficacy of low-dose orally delivered interferon.

Technology - Non-toxic Interferon

Injectable interferon is FDA-approved to treat some neoplastic, viral and autoimmune diseases. Many patients experience moderate to severe side effects that result in discontinuance of injectable interferon therapy. Our product is a natural human interferon alpha delivered into the oral cavity as a lozenge in low (nanogram) doses. The lozenge dissolves in the mouth where interferon binds to surface (mucosal) cells in the mouth and throat resulting in stimulation of immune mechanisms. Orally delivered interferon has been shown to activate hundreds of immune system genes in the peripheral blood. Human studies have shown that oral interferon is effective against viral and autoimmune diseases. Oral interferon is given in concentrations 10,000 times less than that given by injection, resulting in negligible side effects.

Governmental or FDA approval is required for our principal products. Our progress toward approval is discussed under each specific indication, below.

Influenza/Cold - FDA Phase 2 Study

Dr. Manfred Beilharz, Chair of Microbiology and Immunology, Biomolecular and Chemical Sciences at the University of Western Australia recently reported results of a Phase 2 clinical trial in Perth, Australia that showed low-dose interferon lozenges provide an effective, safe and economical form of prophylaxis against colds and influenza. Interferon lozenges were also shown in this study to enhance the effectiveness of seasonal influenza vaccine. We think the implications of this study should help us in attracting a global pharma partner.

Chronic Cough in COPD – FDA Phase 2 study ongoing; funding sought for a second study

COPD affects approximately 10% of the population over 40, is a growing problem, and is the 4th leading cause of death in the world. Chronic obstructive pulmonary disease (COPD) is a clinical condition with a progressive airflow limitation that is poorly reversible and characteristic of chronic bronchitis and emphysema. The causes of COPD include tobacco smoke, occupational dusts, chemicals, vapors and environmental pollutants. COPD is estimated to affect more that 600 million people worldwide. There are no effective therapies for emphysema, nor are there efficient clinical management strategies.

Data from a Phase 2 clinical study at Texas Tech University shows that treatment with oral interferon leads to a rapid and significant reduction in the cough associated with idiopathic pulmonary fibrosis (IPF), resulting in improved quality of life. IPF is similar to COPD in that both diseases lead to a chronic cough in the majority of sufferers through inflammation of the airways. A proof-of-concept study of low-dose oral interferon as treatment of chronic cough is ongoing at Texas Tech University. The study will evaluate the ability of oral interferon to reduce the frequency and severity of chronic cough, compared to placebo.

Hepatitis C - FDA Phase 2 study ongoing

CytoPharm, Inc., our licensee for Taiwan and China, is funding an ongoing Phase 2, placebo-controlled, dose-ranging study of 165 hepatitis C virus-infected patients in Taiwan. The study is designed to test the ability of oral interferon to reduce the virologic relapse rate of patients who have completed standard therapy with pegylated interferon plus ribavirin. Preliminary results are expected in the second half of 2011.

Oral Warts in HIV+ Patients – FDA Phase 2 study completed

Oral warts are lesions in the mouth caused by the human papillomavirus. The FDA has granted Orphan Drug Designation to us for interferon in the treatment of oral warts in HIV+ patients. In Phase 1/2 clinical studies of 36 HIV+ patients with multiple oral warts who were receiving highly active antiretroviral therapy (HAART), efficacy of oral interferon was observed when about 1/3 of the treated subjects achieved a complete or nearly complete regression of their warts.

In a Phase 2 double-blind follow-up study, 31% of evaluable subjects in the IFN group had a 75% or greater reduction in their mouth warts (complete response), compared to only 17% of the subjects in the placebo group. None of the subjects in the placebo group had a 75% or greater reduction in their lip warts, but 39% of the evaluable subjects in the IFN group met this criterion for complete response. However, given the small number of subjects with lip warts and the failure of the study to achieve full enrollment, neither of these differences in favor of IFN over placebo was statistically significant. Oral IFN treatment was found to be safe in this study as there were no increases in adverse event frequency or severity, compared to placebo.

Strategic Alliance with HBL

Hayashibara Biochemical Laboratories, Inc. (“HBL”) was established in 1970 to engage in research and development. It is a subsidiary of Hayashibara Company, Ltd., a privately-owned Japanese holding corporation with diversified subsidiaries. For more than 130 years, the Hayashibara Company, Ltd. and its predecessors have been applying microbiological technology to the starch industry for the production of maltose and other sugars.

In 1981, HBL established the Fujisaki Institute to accelerate development of industrial methods for the production of biologics and to sponsor clinical trials for such products. In 1985, HBL built the Fujisaki Cell Center to support basic research. In 1987, HBL successfully accomplished the mass production of human cells in an animal host by producing human cells in hamsters. This made it possible to economically produce a natural form of human interferon alpha and other biologics. HBL also has developed and obtained patents for technology relating to the production of interferon alpha-containing lozenges by which the stability of the interferon alpha activity can be maintained for up to 24 months at room temperature and up to five years if the product is refrigerated. We believe that the use of such lozenges gives us advantages over competitive technologies in terms of cost, taste and ease of handling. On March 13, 1992, we entered into a Joint Development and Manufacturing/

Supply Agreement with HBL (the “Development Agreement”). Such Development Agreement was subsequently amended on January 17, 1996; May 10, 1996; and September 7, 2001. The current expiration date of the Development Agreement is March 12, 2011, at which time it will automatically renew for an additional three (3) years, unless the parties agree otherwise. Among other things, the Development Agreement provides us with a source of natural human interferon alpha for use in the Company’s interferon alpha-containing products.

Strategic Alliance with Nobel.

We signed a licensing and supply agreement in September 2004 with a Turkish pharmaceutical company, NOBEL ILAC SANAYII VE TICARET A.S., providing the rights to oral low-dose interferon-alpha for the treatment of Behcet’s disease in Turkey and in Azerbaijan, Bosnia & Herzegovina, Bulgaria, Croatia, Georgia, Kazakhstan, Kyrghyzstan, Macedonia, Romania, Russia, Saudi Arabia, Slovenia, Tajikistan, Turkmenistan, Uzbekistan, and Federal Republic of Yugoslavia.

Strategic Alliance with Bumimedic.

In January 2006 we entered into a license and distribution agreement with Bumimedic (Malaysia) Sdn. Bhd, a Malaysian pharmaceutical company that is a part of the Antah HealthCare Group, to market our low-dose interferon (natural human IFN) in Malaysia. Bumimedic will seek registration for our natural human IFN and commence marketing the product after approval. The terms of the agreement call for Bumimedic to manufacture lozenges from our bulk natural human IFN (which is supplied by Hayashibara Biochemical Laboratories); package the lozenges and distribute them to local hospitals, pharmacies and clinics in Malaysia. Pursuant to the agreement, we will receive a series of payments, in three stages: upon formal execution of the distribution agreement, upon regulatory approval, and upon production. We will also receive a royalty on the sale of the natural human IFN.

Strategic Alliance with CytoPharm.

In November 2006, we entered into a License and Supply Agreement with CytoPharm, Inc., a Taipei, Taiwan-based biopharmaceutical company whose parent company is Vita Genomics, Inc., the largest biotech company in Taiwan specializing in pharmacogenomics and specialty Clinical Research Organization. Under the terms of the Agreement, CytoPharm and its subsidiary will conduct all clinical trials, and seek to obtain regulatory approvals in both China and Taiwan (the “Territory”) to launch our low dose oral interferon in the Territory for influenza and hepatitis B (“HBV”) and hepatitis C (“HCV”) indications. According to the Agreement, CytoPharm will make payments to us upon reaching certain milestones and will also pay royalties on low dose oral interferon sales in the Territory.

In March 2008, we entered into a Supply Agreement for Animal Health with CytoPharm, Inc. Under the terms of the Agreement, CytoPharm will conduct all clinical trials, and seek to obtain regulatory approvals in China and Taiwan (the “Territory”) to launch our low dose oral interferon in the Territory for treatment of diseases and other healthcare applications of swine, cattle and poultry. CytoPharm will make payments to us upon reaching certain milestones and will also pay royalties on low dose oral interferon sales in the Territory.

Strategic Alliance with Cyto Biotech.

On February 6, 2009, we entered into a 15-year License and Supply agreement with Cyto Biotech, Inc. a Taipei, Taiwan animal health company. Under the terms of the agreement, Cyto Biotech, will, at its sole expense and cost, conduct all clinical trials and studies and seek to obtain regulatory approvals in China, Taiwan, Thailand, the Philippines, Cambodia, Vietnam

and Malaysia ("the Territory”), subject to the existing license and supply agreements with CytoPharm, Inc. and Bumimedic SDN. BHD., required for the commercial launch of our low dose oral interferon in the Territory for any animal and human health indications.

Cyto Biotech purchased common stock, included in the above issuances in Amarillo Biosciences stock; paid an initial license fee to us; and will pay a net royalty on low dose oral interferon sales. In addition, the agreement calls for certain minimum royalty payments to be made.

Strategic Alliance with Intas Pharmaceuticals.

Nutraceutical Product. We sell anhydrous crystalline maltose (ACM) as Maxisal® to individuals and to pharmacies in the USA and to licensed distributors overseas. We seek to out-license Maxisal®.

Equity Funding. In the first quarter of 2010, the Company sold 1,060,000 unregistered shares of common stock for $0.10 per share plus 1,060,000 3-year warrants with $0.10 exercise price. Net proceeds from private placement stock sales totaled $103,000 after payment of $3,000 in commissions. The Board extended incentives encouraging option and warrant holders to exercise options and warrants until January 22, 2010. An officer and a consultant exercised 82,000 options at $0.10 per share to purchase 82,000 shares of unregistered common stock. The officer and consultant also exercised a total of 163,000 cashless options at $0.10 per share resulting in the issuance of 70,258 unregistered shares of common stock with 92,742 shares of common stock previously held in reserve for options returned to the Treasury. The incremental fair value of the option exercise inducement was $4,456, which was recognized as an expense. Net proceeds from the private placement stock sales and option exercises totaled $111,200 during the first quarter of 2010. Two consultants were issued 135,814 registered shares and 10,000 unregistered shares of common stock for $18,080 and $1,050 of services, respectively.

In the second quarter of 2010, the Company sold 1,075,000 unregistered shares of common stock for $0.10 per share plus 1,075,000 3-year warrants with $0.10 exercise price. Net proceeds from private placement stock sales totaled $97,000 after payment of $10,500 in commissions. One consultant was issued 90,343 shares of common stock in exchange for $8,630 of services.

Results of Operations for Quarters Ended June 30, 2010 and 2009:

Revenues. During the quarter ended June 30, 2010, $3,024 from dietary supplement sales compared to $96 of dietary supplement sales only for the quarter ended June 30, 2009, an increase of $2,928. During the quarter ended June 30, 2010, no sublicense fee was generated compared to $13 sublicense fee the quarter ended June 30, 2009.

Research and Development Expenses. Research and development expenses of $97,831 were incurred for the quarter ended June 30, 2010, compared to $108,986 for the quarter ended June 30, 2009, a decrease of $11,155 (10%). The decrease was because oral warts and influenza were mostly completed in 2009. The costs consisted primarily of personnel and insurance costs.

Selling, General and Administrative Expenses. Selling, general and administrative expenses of $137,403 were incurred for the second quarter in 2010, compared to $434,564 for the second quarter of 2009, a decrease of $297,161 (68%). Most of this decrease was from lower employee and director compensation costs in the second quarter of 2010.

Change in Fair Value of Derivative Instruments. Change in fair value of derivative instruments was realized as a $784,056 gain in the second quarter of 2010 compared to $1,867,012 loss in the second quarter of 2009. Derivative liabilities decreased $2,651,068 from June 30, 2009 to June 30, 2010 mostly because our stock price declined from $0.17 on June 30, 2009 to $0.07 on June 30, 2010.

Other Income. During the three-month period ended June 30, 2010, $140 of interest and other income was generated compared to $1,431 from interest and other income for the quarter ended June 30, 2009. During the second quarter of 2009, interest and other income was mostly derived from the sale of office furniture.

Net Operating Loss. In the three-month period ended June 30, 2010, the Company's net operating loss was $234,248 compared to a net operating loss for the three-month period ended June 30, 2009 of $543,476, a $309,228 (57%) reduction. The operating loss was lower mostly because compensation costs for employees and directors were lower in the first three months of 2010.

Net Income (Loss). In the three-month period ended June 30, 2010, net income was $526,373 compared to a net loss for the three-month period ended June 30, 2009 of $2,431,912, an increase in net income of $2,958,285 (122%). This reduction was mostly the $2,651,068 difference in derivative gains in the second quarter of 2010 and derivative losses in the second quarter of 2009. The $297,161 reduction in general and administrative costs during the second quarter of 2010 compared to the second quarter of 2009 also contributed to the difference.

Results of Operations for the Six Months Ended June 30, 2010 and June 30, 2009

Revenues. During the six months ended June 30, 2010, $3,120 from dietary supplement sales were generated compared to $228 of dietary supplement sales only for the six months ended June 30, 2009, an increase of $2,892. During the six months ended June 30, 2010, no sublicense fee was generated compared to $795 sublicense fees the six months ended June 30, 2009.

Research and Development Expenses. Research and development expenses of $199,119 were incurred for the six month period ended June 30, 2010, compared to $279,937 for the six month period ended June 30, 2009, a decrease of $80,818 (29%). Research and development costs were lower the first six months of 2010 because oral warts in HIV+ patients and influenza studies were mostly completed in 2009. The costs consisted primarily of personnel and insurance costs.

Selling, General and Administrative Expenses. Selling, general and administrative expenses of $312,567 were incurred for the six-month period ended June 30, 2010, compared to $682,088 for the six-month period ended June 30, 2009, a decrease of $369,521 (54%). General and administrative expenses were lower in the six months ended June 30, 2010 mostly because compensation costs for employees and directors were $372,386 (71%) lower than in the first six months of 2009.

Change in Fair Value of Derivative Instruments. Change in fair value of derivative instruments was realized as an $847,790 gain for the six-month period ended June 30, 2010 compared to $1,991,736 loss in the six-month period ended June 30, 2009. Derivative liabilities decreased $2,839,526 from

June 30, 2009 to June 30, 2010 mostly because our stock price declined from $0.17 on June 30, 2009 to $0.07 on June 30, 2010.

Interest and Other Income. During the six-month period ended June 30, 2010, $140 of interest and other income was generated compare to $3,391 in the six-month period ended June 30, 2009, a decrease of $3,251(96%). Interest and other income was higher during the first six months of 2009 mostly because the Company sold some office furniture.

Net Operating Loss. In the six-month period ended June 30, 2010, the Company's net operating loss was $510,661 compared to a net operating loss for the six-month period ended June 30, 2009 of $961,453, a $450,792 (47%) reduction. The operating loss was lower mostly because general and administrative compensation costs for employees and directors were $372,386 lower in the first six months of 2010. Also, Research and development costs were $80,818 lower in the first six months of 2010.

Net Income (Loss). In the six-month period ended June 30, 2010, net income was $290,926 compared to a net loss for the six-month period ended June 30, 2009 of $2,995,508, an increase in net income of $3,286,434 (110%). The increase was mostly the $2,839,526 difference in derivative gains in the first six months of 2010 and derivative losses in the first six months of 2009. The $372,386 reduction in general and administrative costs during the first six months of 2010 compared to the first six months of 2009 also contributed to the difference.

Liquidity Needs: On June 30, 2010, the Company had available $21,300 cash and had a working capital deficit (current assets less current liabilities) of $4,253,715. Current liabilities include two $1 million notes, $705,924 of accrued interest and $78,360 of accrued expenses owed to Hayashibara Biochemical Laboratories, Inc. (HBL), the Company’s second largest shareholder. Accrued payroll and vacation expenses owed mostly to officers is $263,591. Derivative liabilities from warrants with embedded variable features valued at $1,080,330 are also included in the working capital deficit. That leaves approximately $125,510 of accounts payables and accrued expenses in the working capital deficit.

Assuming there is no decrease in current accounts payable, and accounting for various one–time expenses, the Company’s negative cash flow for operating activities plus equipment purchases and patent filings, the Company’s cash burn rate is approximately $61,000 per month (excluding approximately $4,600 per month of consultant fees paid in stock). The Company's continued losses and lack of liquidity raise substantial doubt about whether the Company is able to continue as a going concern for a reasonable period of time. The Company's ability to continue as a going concern is dependent upon several factors including, but not limited to, the Company's ability to generate sufficient cash flows to meet its obligations on a timely basis, obtain license and milestone fees, obtain additional financing and continue to obtain supplies and services from its vendors. The Company will need to raise additional funds in order to fully execute its 2010 Plan. The Company is currently pursuing potential investors for funding. In addition, the Company is also pursuing potential pharmaceutical partners to provide upfront license fee payments and funding for clinical studies. There can be no assurance that private placement funding or pharmaceutical partner funding will become available.

Forward-Looking Statements: Certain statements made in this Plan of Operations and elsewhere in this report are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance, achievements,

costs or expenses and may contain words such as "believe," "anticipate," "expect," "estimate," "project," "budget," or words or phrases of similar meaning. Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from those projected in the forward-looking statements. Such risks and uncertainties are detailed from time to time in reports filed by the Company with the Securities and Exchange Commission, including Forms 8-K, 10-Qand 10-K and include among others the following: promulgation and implementation of regulations by the U.S. Food and Drug Administration ("FDA"); promulgation and implementation of regulations by foreign governmental instrumentalities with functions similar to those of the FDA; costs of research and development and clinical trials, including without limitation, costs of clinical supplies, packaging and inserts, patient recruitment, trial monitoring, trial evaluation and publication; and possible difficulties in enrolling a sufficient number of qualified patients for certain clinical trials. The Company is also dependent upon a broad range of general economic and financial risks, such as possible increases in the costs of employing and/or retaining qualified personnel and consultants and possible inflation which might affect the Company's ability to remain within its budget forecasts. The principal uncertainties to which the Company is presently subject are its inability to ensure that the results of trials performed by the Company will be sufficiently favorable to ensure eventual regulatory approval for commercial sales, its inability to accurately budget at this time the possible costs associated with hiring and retaining of additional personnel, uncertainties regarding the terms and timing of one or more commercial partner agreements and its ability to continue as a going concern.

The risks cited here are not exhaustive. Other sections of this report may include additional factors which could adversely impact the Company's business and future prospects. Moreover, the Company is engaged in a very competitive and rapidly changing industry.

New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the Company's business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those projected in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual future events.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk.

We may not be able to adequately protect and maintain our intellectual property. Our success will depend in part on our ability to protect and maintain our patents, intellectual property rights and licensing arrangements for our products and technology. We currently own three patents and license seven patents. No assurance can be given that such licenses or rights used by us will not be challenged, infringed or circumvented or that the rights granted thereunder will provide competitive advantages to us. Furthermore, there can be no assurance that we will be able to remain in compliance with our existing or future licensing arrangements. Consequently, there may be a risk that licensing arrangements are withdrawn with no penalties to the licensee or compensation to us.

We rely on third parties for the supply, manufacture and distribution of our products. Third parties manufacture and distribute all of our products. We do not currently have manufacturing facilities or personnel to independently manufacture our products. Currently, Marlyn Nutraceutical manufactures our nutraceutical products. Our licensed distributors, located in the United States and internationally, distribute the products. Except for any contractual rights and remedies that we may have with our manufacturer and our distributors, we have no control over the availability of our products, their quality or cost or the actual distribution of our products. If for any reason we are unable to obtain or

retain third-party manufacturers and distributors on commercially acceptable terms, we may not be able to produce and distribute our products as planned. If we encounter delays or difficulties with our contract manufacturer in producing or packaging our products or with our distributor in distributing our products, the production, distribution, marketing and subsequent sales of these products would be adversely affected, and we may have to seek alternative sources of supply or distribution or abandon or sell product lines on unsatisfactory terms. We may not be able to enter into alternative supply, production or distribution arrangements on commercially acceptable terms, if at all. There can be no assurance that the manufacturer that we have engaged will be able to provide sufficient quantities of these products or that the products supplied will meet with our specifications or that our distributor will be able to distribute our products in accordance with our requirements.

We are dependant on funding from private placements of stock. Our sales revenue, sublicense fees and royalty income are negligible compared to expenses. Our primary focus is to achieve FDA approval of oral interferon for one or more disease indications. We do not expect significant sales or royalty revenue in the near term as Phase 2 and Phase 3 clinical studies must be completed before a NDA (New Drug Application) may be submitted to the FDA. We operate at a net loss and current liabilities exceed current assets by $4,253,715. The working capital deficit includes two $1 million notes, $705,924 of accrued interest and $78,360 of accrued expenses owed to our second largest shareholder (HBL); $263,591 of accrued payroll and vacation expenses owed mostly to officers; and $1,080,330 of non-cash derivative liabilities for warrants with embedded derivatives. The remaining working capital deficit of approximately $125,510 consists of accounts payable and accrued expenses.

The Company is currently pursuing potential investors for funding. In addition the Company is also pursuing potential pharmaceutical partners to provide upfront license fee payments and funding for clinical studies. There can be no assurance that private placement funding or pharmaceutical partner funding will become available.

We are dependent on certain key existing and future personnel. Our success will depend, to a large degree, upon the efforts and abilities of our officers and key management employees such as Dr. Joseph M. Cummins, our President and Chief Executive Officer, Bernard Cohen, our Chief Financial Officer, and Martin J. Cummins, our Vice President of Clinical and Regulatory Affairs. The loss of the services of one or more of our key employees could have a material adverse effect on our operations. We do currently have employment agreements with our executive officers. We do not currently maintain key man life insurance on any of our key employees. In addition, as our business plan is implemented, we will need to recruit and retain additional management and key employees in virtually all phases of our operations. We cannot assure that we will be able to successfully attract and retain key personnel.

If we do not successfully develop, acquire or license new drugs our business may not grow. We must invest substantial time, resources and capital in identifying and developing new drugs, dosage and delivery systems, either on our own or by acquiring and licensing such products from third parties. Our growth depends, in part, on our success in such process. If we are unable to either develop new products on our own or acquire licenses for new products from third parties, our ability to grow revenues and market share may be adversely affected. In addition, we may not be able to recover our investment in the development of new drugs, given that projects may be interrupted, unsuccessful, not as profitable as initially contemplated or we may not be able to obtain necessary financing for such development if we are unable to fund such development from our future revenues. Similarly, there is no assurance that we can successfully secure such rights from third parties on an economically feasible basis.

Our competitors are much larger and more experienced than we are and, even if we complete the development of our drugs, we may not be able to successfully compete with them. The pharmaceutical industry is highly competitive. Our biologics and low-dose oral interferon alpha applications compete with high dose injectable interferon manufactured by Roche, Schering, InterMune, Serono, Biogen, and Berlex. High dose injectable interferon has been widely accepted by the medical community for many years. Companies who manufacture injectable interferon alpha applications are more established than we are and have far greater financial, technical, research and development, sales and marketing, administrative and other resources than we do. Even if we successfully complete the development of our tests, we may not be able to compete effectively with these much larger companies and their more established products.

We have been the subject of a going concern opinion by our independent auditors who have raised substantial doubt as to our ability to continue as a going concern. Our Independent Registered Public Accounting firm has added an explanatory paragraph to their audit reports issued in connection with our financial statements for December 31, 2009 and 2008 which states that our recurring losses from operations and the need to raise additional financing in order to execute our business plan raise substantial doubt about our ability to continue as a going concern. We have experienced a net income of $290,926 for the six months ended June 30, 2010 and a net loss of $2,995,508 for the six months ended June 30, 2009. The operating loss for the six months ended June 30, 2010 was $510,661 but was offset by a non-cash accounting gain of $847,790 from the change in fair value of derivative instruments. In addition, as of June 30, 2010 we had an accumulated deficit of $35,028,013. These factors, among others, raise substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustment that might result from the outcome of this uncertainty. Assurances cannot be given that adequate financing can be obtained to meet our capital needs. We have already significantly curtailed operations, and if we are unable to generate profits and if we to continue to be unable to obtain financing to meet our working capital requirements, we will have to cease operations altogether. Our continuation as a going concern is dependent upon our ability to generate sufficient cash flow to meet our obligations on a timely basis, to retain our current financing, to obtain additional financing, and, ultimately, to attain profitability.

Risk Relating to Our January 2008 Financing Arrangement. There are 12,477,999 shares underlying our warrants related to our January 2008 financing arrangement that may be available for future sale and the sale of these shares may depress the market price of our common stock. In addition the warrants have an anti-dilution ratchet feature that could cause the number of warrants to increase and the exercise price to decrease if we should have any non exempt stock, option or warrant issuances less the $0.10 per share. As of June 30, 2010, we had 54,564,416 shares of common stock issued and outstanding plus 26,712,096 shares reserved for options and warrants which includes the above January 2008 warrants.

Risks Related to our Common Stock. There is only a limited market for our common stock and the price of our common stock may be affected by factors that are unrelated to the performance of our business. If any of the risks described in these Risk Factors or other unseen risks are realized, the market price of our common stock could be materially adversely affected. Additionally, market prices for securities of biotechnology and diagnostic companies have historically been very volatile. The market for these securities has from time to time experienced significant price and volume fluctuations for reasons that are unrelated to the operating performance of any one company. In particular, and in addition to the other risks described elsewhere in these Risk Factors, the following factors can adversely affect the market price of our common stock:

announcements of technological innovation or improved or new diagnostic products by others;

general market conditions;

changes in government regulation or patent decisions;

changes in insurance reimbursement practices or policies for diagnostic products.

Our common shares have traded on the Over the Counter Bulletin Board at prices below $5.00 for several years. As a result, our shares are characterized as “penny stocks” which could adversely affect the market liquidity of our common stock. The Securities Enforcement and Penny Stock Reform Act of 1990 requires additional disclosure relating to the market for penny stocks in connection with trades in any stock defined as a penny stock. Securities and Exchange Commission regulations generally define a penny stock to be an equity security that has a market price of less than $5.00 per share, subject to certain exceptions. Such exceptions include any equity security listed on NASDAQ or a national securities exchange and any equity security issued by an issuer that has:

net tangible assets in excess of $2,000,000, if such issuer has been in continuous operation for three years;

net tangible assets in excess of $5,000,000, if such issuer has been in continuous operation for less than three years; or

average revenue of at least $6,000,000, for the last three years.

Unless an exception is available, the regulations require, prior to any transaction involving a penny stock, that a disclosure schedule explaining the penny stock market and the risks associated therewith is delivered to a prospective purchaser of the penny stock. We currently do not qualify for an exception, and, therefore, our common stock is considered to be penny stock and is subject to these requirements. The penny stock regulations adversely affect the market liquidity of our common shares by limiting the ability of broker/dealers to trade the shares and the ability of purchasers of our common shares to sell in the secondary market. In addition, certain institutions and investors will not invest in penny stocks.

Future sales of a significant number of shares of our common stock by existing stockholders may lower the price of our common stock, which could result in losses to our stockholders. Approximately 2,300,000 restricted shares were issued during the six months ended June 30, 2010 which, upon becoming freely tradable under Rule 144 or 144(k) of the Securities Exchange Act of 1934, may lower the price of our common stock. The number of shares of restricted stock issued prior to September 1, 2009 that has been held for at least six months and hasn’t had the legends removed to become freely tradable under Rule 144 or 144(k) is not known.

ITEM 4. Controls and Procedures

As required by Rule 13a-15 under the Exchange Act, we have carried out an evaluation of the effectiveness of the design and operation of our company’s disclosure controls and procedures as of the end of the period covered by this quarterly report, being June 30, 2010. This evaluation was

carried out under the supervision and with the participation of our company’s management, including our company’s president and chief executive officer. Based upon that evaluation, our company’s president and chief executive officer concluded that our company’s disclosure controls and procedures are effective as at the end of the period covered by this report. There have been no significant changes in our company’s internal controls or in other factors, which could significantly affect internal controls subsequent to the date we carried out our evaluation.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our company’s reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Exchange Act is accumulated and communicated to management, including our company’s president and chief executive officer as appropriate, to allow timely decisions regarding required disclosure.

There were no changes in internal controls over financial reporting during the period ended June 30, 2010.

PART II - OTHER INFORMATION

ITEM 1. Legal Proceeding.

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. As of the date of this report, we were not aware of any such legal proceedings or claims against us.

ITEM 2.

Unregistered Sales of Equity Securities and Use of Proceeds

During the first quarter of 2010, the Company sold 1,060,000 unregistered shares of common stock for $0.10 per share plus 1,060,000 3-year warrants with $0.10 exercise price. Net proceeds from private placement stock sales totaled $103,000 after payment of $3,000 in commissions. The Board extended incentives encouraging option and warrant holders to exercise options and warrants until January 22, 2010. An officer and a consultant exercised 82,000 options at $0.10 per share to purchase 82,000 shares of unregistered common stock. The officer and consultant also exercised a total of 163,000 cashless options at $0.10 per share resulting in the issuance of 70,258 unregistered shares of common stock with 92,742 shares of common stock previously held in reserve for options returned to the Treasury. The incremental fair value of the option exercise inducement was $4,456, which was recognized as an expense. Net proceeds from the private placement stock sales and option exercises totaled $111,200 during the first quarter of 2010. One consultant was issued 10,000 unregistered shares of common stock for services valued at $1,050.

The chart below details unregistered issuances of common stock.

	Date (2010)	Shares of Common Stock			Purchaser	Discount1
	Date (2010)	Issue Price		Number	Purchaser	Per Share		Total
1	January 72	$	.10	100,000	Dan Mascarenhas	$	0.08	$	8,000
2	January 113		.10	30,000	Dr. Joseph Cummins		0.071		2,130
3	January 114		.175	25,714	Dr. Joseph Cummins		0		0

4	January 185	.10	500,000	Thomas Ulie	.07	35,000
5	January 196	.10	10,000	Dr. Kimball Miller	.0763	7,630
6	January 227	.10	52,000	Dr. Gary Coy	.07	3,640
7	January 228	.1762	44,544	Dr. Gary Coy	0	0
8	February 99	.10	50,000	David Min	.0329	1,645
9	March 1210	.10	150,000	Marian Tibbits	.005	750
10	March 1210	.10	150,000	Paul Tibbits	.005	750
11	March 12	.105	10,000	George Bergleitner, Jr.	0	0
12	March 2911	.10	50,000	Robert Costes	.025	1,250
13	March 2911	.10	50,000	Joanna Costes	.025	1,250
14	April 1512	.10	100,000	Marian Tibbits	.02	2,000
15	April 1512	.10	100,000	Paul Tibbits	.02	2,000
16	April 2613	.10	25,000	David Minn	.0198	495
17	May 714	.10	150,000	Marian Tibbits	.0089	1,335
18	May 714	.10	150,000	Paul Tibbits	.0089	1,335
19	June 415	.10	350,000	Paul Tibbits	0	0
20	June 2916	.10	200,000	Virginia Sumner, Trustee	0	0

1.	Discounts were calculated based on the closing price of the last transaction on each date.

2.	The price was $0.10 for each share of common stock and one warrant with three year term and exercisable at $0.20 per share. The stock closing price on January 7, 2010 was $0.18 per share.

3.	Options were exercised for cash. The stock closing price on January 11, 2010 was $0.1701 per share.

4.	A total of 60,000 cashless options were exercised at $0.10 per share. 25,714 shares of common stock were issued and 34,286 shares of common stock held in reserve for options were returned to Treasury. The stock closing price on January 11, 2010 was $.1701 per share.

5.	The price was $0.10 for each share of common stock and one warrant with three year term and exercisable at $0.10 per share. The stock closing price on Friday, January 15, 2010 was $0.17 per share. No shares traded on January 18, 2010.

6.	The price was $0.10 for each share of common stock and one warrant with three year term and exercisable at $0.10 per share. The stock closing price on January 19, 2010 was $0.1763 per share.

7.	Options were exercised for cash. The stock closing price on January 22, 2010 was $0.17 per share.

8.	103,000 cashless options were exercised at $0.10 per share. 44,544 shares of common stock were issued and 58,456 shares of common stock held in reserve for options were returned to Treasury. The stock closing price on January 22, 2010 was $0.17 per share.

9.	The price was $0.10 for each share of common stock and one warrant with three year term and exercisable at $0.10 per share. The stock closing price on February 9, 2010 was $0.1329 per share.

10.	The price was $0.10 for each share of common stock and one warrant with three year term and exercisable at $0.10 per share. The stock closing price on March 6, 2010 was $0.105 per share.

11.	The price was $0.10 for each share of common stock and one warrant with three year term and exercisable at $0.10 per share. The stock closing price on March 29, 2010 was $0.125 per share.

12.	The price was $0.10 for each share of common stock and one warrant with three year term and exercisable at $0.10 per share. The stock closing price on April 15, 2010 was $0.12 per share.

13.	The price was $0.10 for each share of common stock and one warrant with three year term and exercisable at $0.10 per share. The stock closing price on April 26, 2010 was $0.1198 per share.

14.	The price was $0.10 for each share of common stock and one warrant with three year term and exercisable at $0.10 per share. The stock closing price on May 7, 2010 was $0.1089 per share.

15.	The price was $0.10 for each share of common stock and one warrant with three year term and exercisable at $0.10 per share. The stock closing price on June 4, 2010 was $0.076 per share.

16.	The price was $0.10 for each share of common stock and one warrant with three year term and exercisable at $0.10 per share. The stock closing price on June 29, 2010 was $0.08 per share.

ITEM 3.

Defaults Upon Senior Securities.

None, other than set forth in Note 6 to Financial Statements, “Notes Payable”, under Part I, Item 1, above, regarding non-payment of the HBL Notes.

ITEM 4.

Submission of Matters to a Vote of Security Holders.

None.

ITEM.5.

Other Information

None

ITEM 6.

Exhibits.

None

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMARILLO BIOSCIENCES, INC.

Date: August 20, 2010

By: /s/ Joseph M. Cummins

Joseph M. Cummins

President and Chief Executive Officer

Date: August 20, 2010

By: /s/ Bernard Cohen

Bernard Cohen

Vice President and Chief Financial Officer